SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

"What's Updog?" is a Community Led token.

UpDog

The UpDog community is rallying around the token's long-standing presence on the Solana network, with members highlighting active whale accumulation and organic engagement. Discussions are dominated by community members celebrating the project's recent trending status across market platforms and emphasizing the durability of a project that has maintained locked liquidity for over two years.

Chip

Chip is experiencing significant trading volatility following its recent listings on major platforms, sparking intense community debate over its utility in the AI infrastructure sector. While some investors are optimistic about its long-term potential as a governance token for GPU-backed financing, others are raising concerns about suspicious price action and the high volume of insider holdings.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is gaining momentum as investors anticipate major announcements at an upcoming industry conference, driving significant speculation about a potential breakout. The community remains deeply divided, with long-term believers accumulating shares on the expectation of utility-driven adoption while vocal critics dismiss the price action as a pump-and-dump cycle.

Terra is a decentralized financial payment network that rebuilds the traditional payment stack on the blockchain. Luna is the reserve currency of the Terra platform. It has three core functions: i) mine Terra transactions through staking, ii) ensure the price stability of Terra stablecoins and iii) provide incentives for the platform’s blockchain validators.

Terra Luna Classic

Terra Luna Classic is experiencing a surge in social sentiment driven by ongoing community efforts to reduce circulating supply through consistent burn mechanisms and staking rewards. Investors are actively debating the token's potential for a long-term recovery, with many pointing to upcoming ecosystem projects and legislative developments as potential catalysts for future momentum.

Jupiter is a cryptocurrency exchange platform on the Solana blockchain, offering features such as token swapping, limit orders, dollar-cost averaging, and a bridge for asset transfers to Solana. It provides users with tools to find the best trading prices and includes a beta version for perpetual futures trading. Jupiter finds the best price route for your swap by aggregating all the major liquidity sources on Solana.

Jupiter

The community surrounding $UPDOG is actively highlighting the project's longevity on Solana and its presence on the Jupiter strict list, encouraging users to swap via JUP. Traders are also discussing broader market sentiment and utilizing JUP's lending features, despite some community frustration regarding exchange volatility and platform performance.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is trending as the community remains sharply divided between long-term holders accumulating during the accumulation phase and vocal critics frustrated by stagnant price action and lack of communication from leadership. Discussions are heavily focused on the project's long-term utility in data ownership compared to newer ecosystem developments, with investors debating the impact of market cycles on their holdings.

Airgain, Inc. provides embedded antenna products, integration support and test services. The firm works in partnership with the entire ecosystem, including carriers, chipset suppliers, OEMs, and ODMs. Its products include embedded, external and carrier-class antennas. The company offers custom antenna design and performance validation services. Its antennas are deployed in carrier, fleet, enterprise, residential, private, government, and public safety wireless networks and systems, including set-top boxes, access points, routers, modems, gateways, media adapters, and asset tracking devices. The company was founded on March 20,1995 and is headquartered in San Diego, CA.

Airgain Inc

Airgain is trending following the announcement of a multi-million dollar contract to deploy its connectivity solutions across a major U.S. utility's vehicle fleet. Investors are actively debating the company's growth potential and its broader strategic partnerships within the wireless infrastructure and 5G sectors.

TRON is a decentralized blockchain-based operating system designed to accelerate the decentralization of the internet and its underlying infrastructure. It serves as a global settlement layer for stablecoins and everyday digital purchases, providing a high-throughput environment to support large-scale decentralized applications. The network is governed by a decentralized autonomous organization (DAO), which allows the community to manage the protocol without a central authority. Its primary value proposition includes a unique resource model that utilizes bandwidth and energy to allow for high transaction volumes without traditional fee spikes.  The platform functions as a smart contract platform that enables the creation of decentralized applications and is compatible with the Ethereum Virtual Machine, allowing developers to easily migrate applications. TRON operates using a Delegated Proof of Stake consensus mechanism where token holders vote for 27 Super Representatives to verify transactions and maintain the ledger. This structure is built for scalability and fast finality, aiming to handle more transactions per second than many established legacy blockchains. Users can interact with the ecosystem for various purposes, including decentralized finance (DeFi) through platforms like JustLend DAO and decentralized storage via the BitTorrent File System.  Value moves through the system via its native utility token, TRX, which facilitates transactions and grants users access to network resources. Holders can lock their TRX in a staking mechanism to gain TRON Power, which is used to vote on network rules and elect Super Representatives, earning rewards for securing the network. Established by the TRON Foundation and led by founder Justin Sun, the project has transitioned into a community-led DAO. The ecosystem is supported by strategic partnerships with major global entities, including Samsung, which integrated TRON into its blockchain keystore, as well as BitTorrent, Opera, and Swisscom Blockchain.

Tron

Tron (TRX) is currently trending due to its growing utility as a primary infrastructure layer for stablecoin payments and significant integrations with major platforms like Rumble. The community is actively discussing its resilience in volatile market conditions and the strategic impact of its increasing adoption across global financial systems.

Tidal Trust II - Defiance Daily Target 2X Long IONQ ETF

Defiance Daily Target 2X Long IONQ ETF

IONX is trending as traders use the leveraged ETF to capitalize on high-volatility price swings in the underlying quantum computing sector. The community is actively debating the risks of holding the leveraged vehicle through market turbulence, focusing on technical support levels and potential for significant short-term gains.

Listed Funds Trust - Roundhill Magnificent Seven ETF

Roundhill Magnificent Seven ETF

The Roundhill Magnificent Seven ETF is trending as investors debate the sustainability of the AI capex cycle and watch for rotation into other sectors amidst broader market volatility. Community discussion is focused on the ETF's role as a proxy for Big Tech dominance, with some traders monitoring key support levels while others question whether the concentration in these seven names has reached an exhaustion point.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Last year, Financial Times reported that big pharma company Merck had attempted to acquire MoonLake for over $3 billion though the approach was rejected.</li><li>MoonLake over the weekend announced that two of its late-stage trials in Hidradenitis suppurativa (HS) showed that clinical responses continue to improve to Week 40.</li><li>Currently, FDA approved medicines for HS include Novartis’s Cosentyx and AbbVie’s Humira.</li></ul>Shares of MoonLake Immunotherapeutics (MLTX) garnered retail interest on Tuesday on the heels of the company announcing long-term results from its late-stage clinical trials in moderate-to-severe hidradenitis suppurativa.On Stocktwits, retail sentiment around MLTX stock stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume remained at ‘extremely high’ levels.A Stocktwits user highlighted optimism for a buyout for MoonLake, highlighting other recent mergers and acquisitions in the pharma industry, such as Biogen’s buyout of Apellis.<stembedurl>https://www.stocktwits.com/Bigpapa46/message/649036046</stembedurl>Last year, Financial Times reported that big pharma company Merck had attempted to acquire MoonLake for over $3 billion though the approach was rejected.Another user said that they are eyeing the stock breaching $19 levels.<stembedurl>https://www.stocktwits.com/Mr_GA/message/649091749</stembedurl>Yet another lauded the stock as the “Best buy in clinical biopharma,” while adding that it guarantees a “massive payday.”<stembedurl>https://www.stocktwits.com/Creisi/message/649090006</stembedurl><h2 class="st-heading-2">MoonLake’s Recent Data Reveal</h2>MoonLake over the weekend announced that two of its late-stage trials in Hidradenitis suppurativa (HS) showed that clinical responses continue to improve to Week 40, with 62% of patients treated with sonelokimab (SLK) achieving 75% reduction in abscess and inflammatory nodule count. Hidradenitis suppurativa (HS) is a chronic, noncontagious inflammatory skin condition causing painful, recurring lumps and abscesses, often leading to scarring and tunnels under the skin.According to MoonLake, the data sets a new standard in long-term lesion control of HS as approved drugs only reported similar reduction in symptoms for about 40% and 60% of subjects, respectively, at the 1-year mark of their respective pivotal trials.Currently, FDA approved medicines for HS include Novartis’s Cosentyx and AbbVie’s Humira.According to data from Koyfin, 12 of the 16 analysts covering MLTX rate it ‘Buy’ or higher while two rate ‘Hold’ and the remaining two rate it ‘Sell.’ The 12-month average price target on the stock is at $26.71, representing a potential upside of about 41%.<a href="https://stocktwits.com/symbol/MLTX">MLTX stock</a> slumped 52% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/nio-stock-rallies-in-anticipation-of-upbeat-q1-delivery-numbers-after-america-expansion-efforts/cZE5cWMRIVp">Nio Stock Rallies In Anticipation Of Upbeat Q1 Delivery Numbers After America Expansion Efforts</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a MoonLake Immunotherapeutics company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

MLTX Stock Garners Retail Attention On Buyout Speculation, Positive Skin Condition Trial Data

A Stocktwits user highlighted optimism for a buyout for MoonLake, highlighting other recent mergers and acquisitions in the pharma industry, such as Biogen’s buyout of Apellis.

Equity

A Stocktwits user highlighted optimism for a buyout for MoonLake, highlighting other recent mergers and acquisitions in the pharma industry, such as Biogen’s buyout of Apellis.


<ul class="summary-bullets"><li>Merck is currently seeking to fortify its drug portfolio before its blockbuster cancer therapy Keytruda begins to lose patent protection in 2028.</li><li>While there were reports of Merck looking to acquire cancer drugmaker Revolution Medicines in January for about $30 billion, a deal didn’t materialize.</li><li>MoonLake Therapeutics, headquartered in Switzerland, is developing its investigational therapy sonelokimab for the treatment of inflammatory diseases.</li></ul>Shares of MoonLake Immunotherapeutics (MLTX) garnered retail attention on Tuesday amid buyout speculation.On Stocktwits, a retail investor voiced optimism for either a buyout announcement or positive news from the U.S. Food and Drug Administration for the company this week.<stembedurl>https://www.stocktwits.com/Warren_8/message/645090086</stembedurl>Another user, however, said that MoonLake must increase its share price from current levels if it wants to be acquired.<stembedurl>https://www.stocktwits.com/Newcar/message/645134185</stembedurl>Some users also highlighted a potential takeover by pharma major Merck for MoonLake.<stembedurl>https://www.stocktwits.com/Bigpapa46/message/645006814</stembedurl>On Stocktwits, overall retail sentiment around MLTX improved from ‘extremely bearish’ to ‘bearish’ territory over the past 24 hours, while message volume remained at ‘low’ levels.Shares of the company closed 11% higher in the regular trading session. &nbsp;<h2 class="st-heading-2">Is Merck Looking To Acquire Companies?</h2>Merck is currently seeking to fortify its drug portfolio before its blockbuster cancer therapy Keytruda begins to lose patent protection in 2028. Keytruda generated approximately $29.5 billion in global sales for the full year 2024, accounting for about 46% of the company’s overall worldwide sales.The company entered into a deal to acquire Cidara Therapeutics for about $9.2 billion in November. It also agreed to buy respiratory drug developer Verona Pharma for $10 billion in July as part of a broader effort to maintain revenue momentum.While there were reports of Merck looking to acquire cancer drugmaker Revolution Medicines in January for about $30 billion, a deal didn’t materialize as the two companies failed to come to an agreement on price, The Wall Street Journal reported.<h2 class="st-heading-2">MoonLake’s Portfolio</h2>MoonLake Therapeutics, headquartered in Switzerland, is developing its investigational therapy sonelokimab for the treatment of inflammatory diseases such as hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis and palmoplantar pustulosis.Earlier this month, the FDA granted Fast Track designation to sonelokimab in moderate-to-severe palmoplantar pustulosis. The company is also eyeing making an application to the FDA for approval of sonelokimab in hidradenitis suppurativa in the second half of 2026.The company is now slated to hold an investor day event on Feb. 23, 2026.<a href="https://stocktwits.com/symbol/MLTX">MLTX stock</a> has dropped 59% this year.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/help-stock-rallies-after-experimental-depression-drug-reduces-symptoms-in-study/cZRWDUOR4HP">HELP Stock Rallies After Experimental Depression Drug Reduces Symptoms In Study: Retail Thinks Its ‘Time To Buy More’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the MoonLake Immunotherapeutics (Moon Lake) logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

MLTX Stock Gains As Retail Eyes Buyout From Big Pharma, Upcoming Investor Day Event

Some Stocktwits users voiced optimism for the inflammation-drug maker getting acquired by pharma giant Merck. 

<ul class="summary-bullets"><li>H.C. Wainwright raised MoonLake’s price target to $32 from $26 and maintained a ‘Buy’ rating.</li><li>BTIG said the FDA approval ‘clears a significant overhang’ for MoonLake’s clinical program.</li><li>MoonLake plans to submit its biologics license application in the second half of 2026.</li></ul>MoonLake Immunotherapeutics (MLTX) remained on investors’ radar after its shares rose 5% in premarket trading on Friday, following favorable brokerage action tied to positive feedback from the U.S. Food and Drug Administration (FDA) on its treatment for hidradenitis suppurativa, a chronic inflammatory skin condition.<a href="https://stocktwits.com/symbol/MLTX">MLTX</a> was among the top trending tickers on Stocktwits at the time of writing.BTIG upgraded MoonLake Immunotherapeutics to ‘Buy’ from ‘Neutral’ and set a $24 price target, citing a recent regulatory update, according to TheFly.<h2 class="st-heading-2">The FDA Feedback</h2>The FDA <a href="https://stocktwits.com/news-articles/markets/equity/why-did-mltx-stock-jump-45-in-pre-market-today/cmUbJFWR4Pt">confirmed</a> that MoonLake can establish the effectiveness of Sonelokimab (SLK) in hidradenitis suppurativa without additional trials, a development BTIG believes clears a significant overhang for the company’s clinical program and could position SLK for FDA approval.This would be supported by existing data from the VELA-1, VELA-2, and MIRA studies. The company plans to submit its biologics license application in the second half of 2026.H.C. Wainwright raised MoonLake’s price target to $32 from $26 and maintained a ‘Buy’ rating. The company’s FDA meeting outcome delineates a path to registration, the firm said.The stock closed 27% higher on Thursday following the FDA feedback.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits remained in the ‘extremely bullish’ zone over the past 24 hours, accompanied by ‘extremely high’ message volumes.<img src="https://news.stocktwits-cdn.com/MLTX_jpg_6f56883898.webp" alt="MLTX.jpg">One user sees potential conversations regarding mergers and acquisitions following the FDA feedback.<stembedurl>https://stocktwits.com/Atdanaiw/message/641311151</stembedurl>Another user believes MLTX’s value needs to grow further before a probable acquisition.<stembedurl>https://stocktwits.com/Newcar/message/641308484</stembedurl>MoonLake had reportedly turned down a $3 billion acquisition offer from Merck (MRK) in June last year.The stock has been under heavy selling pressure over the past year, declining more than 70%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/glue-stock-slips-pre-market-after-pricing-300-million-public-offer-at-discount/cmU2ghYR4dQ">GLUE Stock Slips Pre-Market After Pricing $300 Million Public Offer At Discount</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.&nbsp;

MLTX Stock Extends Rally As FDA Feedback Spurs Bullish Brokerage Action – Retail Speculates On Potential M&A Conversations

BTIG upgraded MoonLake Immunotherapeutics to ‘Buy’ from ‘Neutral’ after the FDA said the company could show the effectiveness of Sonelokimab without additional HS trials.

<ul class="summary-bullets"><li>The FDA feedback indicates the company can establish&nbsp;substantial evidence of effectiveness without conducting additional&nbsp;hidradenitis suppurativa trials.</li><li>The firm remains on track to submit its Biologic License Application for Sonelokimab in the second half of 2026.</li><li>MoonLake will host an Investor Day on February 23 to review FDA feedback from the Type B meeting.</li></ul>Shares of MoonLake Immunotherapeutics (MLTX) surged 45% in premarket trading on Thursday after the company said it received positive regulatory feedback from the U.S. Food and Drug Administration (FDA) following a Type B meeting regarding Sonelokimab (SLK), a drug used to treat hidradenitis suppurativa (HS), a chronic inflammatory skin disorder.The FDA feedback indicates the company can establish substantial evidence of effectiveness (SEE) without conducting additional HS trials, using a Biologic License Application (BLA) supported by data from its existing VELA-1, VELA-2, and MIRA studies.The agency advised including MIRA results to support efficacy and submitting VELA-2 data to inform the safety profile. Based on the official meeting outcome, the company remains on track to submit its BLA for Sonelokimab in the second half of 2026.“The positive outcome of our Type B meeting with the FDA provides the clarity needed to support a pathway to approval for our existing HS program, with no additional clinical trials required. In addition, the fact that we can prepare the BLA with the wealth of data across the VELA and MIRA trials provides us and the FDA with flexibility to determine the best label possible, so that SLK, if approved, can have the most positive impact for HS patients,” said Jorge Santos da Silva, Founder and Chief Executive Officer at MoonLake Immunotherapeutics.<h2 class="st-heading-2">2026 Pipeline</h2>MoonLake will host an Investor Day on Feb. 23, 2026, to review the FDA feedback from the Type B meeting and share new clinical data for SLK across indications, along with updates to its 2026 catalyst outlook.The company also expects a steady flow of clinical readouts over the next year, including Phase 2 data in axial spondyloarthritis and multiple Phase 3 updates in psoriatic arthritis and HS. Key milestones include a Phase 2 axSpA readout in Q1 2026, several Phase 3 readouts by mid-2026, and a planned BLA submission in the second half of 2026.<h2 class="st-heading-2">How Did Stockwits Users React?</h2>Retail sentiment on Stocktwits turned ‘extremely bullish’ from ‘bullish’ a day earlier, amid ‘high’ message volumes. <a href="https://stocktwits.com/symbol/MLTX">MLTX</a> was among the top trending stocks on the platform at the time of writing.<figure class="image"><img src="https://news.stocktwits-cdn.com/MLTX_jpg_70c33bd6fe.webp" alt="MLTX.jpg" width="916" height="96"><figcaption>MLTX's Sentiment Meter and Message Volumes at Premarket on Jan. 8, 2026 | Source: Stocktwits</figcaption></figure>One user expects the stock to climb to $22 within a few sessions. It is currently trading at $16.2.<stembedurl>https://stocktwits.com/discountcroesus1/message/641193716</stembedurl>The stock has been under heavy selling pressure over the past year, declining nearly 80%.Read Also: <a href="https://stocktwits.com/news-articles/markets/equity/why-vnda-stock-falling-premarket/cmUbEA9R4Pn">Vanda Stock Drops 10% Premarket After FDA Rejects Jet Lag Drug Application</a> For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Did MLTX Stock Jump 45% In Pre-Market Today?

The company said it received positive regulatory feedback from the U.S. FDA following a Type B meeting regarding a drug used to treat hidradenitis suppurativa, a chronic inflammatory skin disorder.

Current Price	$51.15
Prev Close	$50.98
Open	$51.26
Dividend Yield	N/A
50-Day Moving Average	$48.74
Beta	N/A
Avg. Volume	227,940.50
PE Ratio	N/A

52-Week High	$51.95
52-Week Low	$36.65
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

ESML
iShares ESG Aware MSCI USA Small-Cap ETF

Feed

News

Sentiment

Fundamentals

Info

Latest ESML News

ESMLiShares ESG Aware MSCI USA Small-Cap ETF